Biohacker, entrepreneur and Blueprint creator wi

Elon Musk’s neurotech company valued at $9 bil

Circulate Health and Buck researchers find that

Salk study finds ERRs as vital to mitochondrial

Clinical stage biotech gears up for industry fir

VITAL sub-study shows vitamin D may help preserv

Stanford and Rubedo researchers identify pain-dr

University of Copenhagen receives Longevity Scie

Polypharmacology meets machine learning as resea

Longevity biotech sector consolidates as cellula

Stately Bio founder explains how combining machi

Southern California initiative to focus on early

Controversial sporting event that encourages per

Tomorrow.

Epigenetic lineage tracing offers insight into h

Companies to collaborate on new Abu Dhabi drug d

Regeneron’s $256 million acquisition marks a p

San Francisco’s Frontier Tower transforms urba

Rejuvenate Biomed to study how metformin-galanta

New paper proposes tackling aging organ by organ

Natural endocrine therapy is designed to help re

Startup targets developmental biology’s ‘Alp

Exclusive investor event brings together scienti

Longevity field hails ‘landmark step’ as US

Targeting toxic fibrin deposits, startup seeks t

New data suggests treatment with Wegovy offers ‘remarkable’ cardioprotective effects – before significant weight loss occurs. This week, Danish pharma giant Novo Nordisk announced new data highlighting the early cardiovascular benefits of Wegovy at the European Congress of Obesity. The company presented a secondary analysis from the Phase 3 SELECT trial, which revealed that Wegovy reduced the risk of major adverse cardiovascular events – including cardiovascular death and non-fatal heart attacks – by 37% compared with placebo within the first three months of treatment. Within six months, the risk of death from cardiovascular disease was halved, and the likelihood of hospitalization or urgent care for heart failure or cardiovascular death was reduced by 59%. Crucially from a longevity perspective, these early protective effects were observed before patients achieved significant weight loss, suggesting that Wegovy’s cardiovascular benefits are not solely attributable to its impact on body weight but may also involve direct effects on cardiovascular physiology. “Seeing this SELECT secondary data demonstrate that patients experienced MACE risk reduction within three months is remarkable,” said Novo Nordisk’s head of medical Dr Jason Brett. The SELECT trial, which enrolled over 17,000 adults aged 45 and older with overweight or obesity and established cardiovascular disease…

As the clinical phase begins, Peter Diamandis ou

Petro Trush on turning wartime biotech into peac

New report reveals $8.

Non-profit pours grant funding into research foc

Startup lands $65m and targets clinical trials o

Global competition enters clinical phase as sele

Drug based on naturally occurring protective ant

Foresight model aims to predict disease risk for

2060 Foundation President Gabriel Cian on buildi

Researchers hope to ‘steal’ protein modifica

Acquisition provides access to key longevity dat

Prescription device delivers at-home vibration t

After rejuvenating liver and immune cells, start

Preventive health platform to offer $499 scans a

Researchers create personalized biological clock

Senolytics company announces full 36-week data f

New paper argues that targeting the biology of a

Fountain Life Co-founder and CEO Bill Kapp on wh

Startup founded by former Calico researcher aims

UNITY Biotechnology CEO on recent trial results

Following positive Phase 1 trial results, fibrin

Continued development of Oviva’s platform to i

New research reveals how disrupted mitochondrial

New research reveals senescence is not a single